Top 30 Regulatory Affairs Interview Questions & Answers

Top 30 Regulatory Affairs Interview Questions & Answers

Top 10 Pharmaceutical Interview Questions and Answers

 

17) What are the types of active substances for which ASMFs are submitted?

  • New active substances
  • Existing active substances not included in the European Pharmacopoeia (Ph. Eur.) or the pharmacopoeia of an EU Member State
  • Pharmacopeial active substances included in the Ph. Eur. or in the pharmacopoeia of an EU Member State

 

18) What is the difference between DMF and ASMF (with respect to submission)?

ASMF is submitted as Applicant’s Part (Open Part) and Restricted Part (Closed Part)

There isn’t any differentiation of DMF’s into parts

19) What is ICH?

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of pharmaceutical product registration.

20) What is CTD?

The Common Technical Document (CTD) is a set of specification for application dossier, for the registration of Medicines and designed to be used across Europe, Japan and the United States.Quality, Safety and Efficacy information is assembled in a common format through CTD .The CTD is maintained by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

CTD format for submission of drug registration applications/dossiers is widely accepted by regulatory authorities of other countries too like Canada, Australia etc.

 

21) What are the ICH guidelines to be referred for preparation of registration dossiers/applications of medicines (With respect to format and contents in each module)?

M4   Guideline

M4Q Guideline

M4S Guideline

M4E Guideline

22) What are the modules in CTD?

The Common Technical Document is divided into five modules:

Module 1. Administrative information and prescribing information

Module 2. Common Technical Document summaries (Overview and summary of modules 3 to 5)

Module 3. Quality

Module 4. Nonclinical Study Reports (toxicology studies)

Module 5. Clinical Study Reports (clinical studies)

23) What is Orange Book?

  • It is the commonly used name for the book “Approved Drug Products with Therapeutic Equivalence Evaluations”, which is published by USFDA.
  • It contains the list of drug products, approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act.

24) What is Hatch-Waxman act?

It is the popular name for Drug Price Competition and Patent Term Restoration Act, 1984. It is considered as the landmark legislation which established the modern system of generic drugs in USA. Hatch-Waxman amendment of the federal food, drug and cosmetics act established the process by which, would be marketers of generic drugs can file Abbreviated New Drug Application (ANDA) to seek FDA approval of generic drugs. Paragraph IV of the act, allows 180 day exclusivity to companies that are the “first-to-file” an ANDA against holders of patents for branded counterparts.

In simple words “Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics ”

25) What are the patent certifications under Hatch-Waxman act?

As per the Hatch and Waxman act, generic drug and 505 (b) (2) applicants should include certifications in their applications for each patent listed in the “Orange Book” for the innovator drug. This certification must state one of the following:

(I) that the required patent information relating to such patent has not been filed (Para I certification);

(II) that such patent has expired (Para II certification);

(III) that the patent will expire on a particular date (Para III certification); or

(IV) that such patent is invalid or will not be infringed by the drug, for which approval is being sought(Para IV certification).

A certification under paragraph I or II permits the ANDA to be approved immediately, if it is otherwise eligible. A certification under paragraph III indicates that the ANDA may be approved when the patent expires.

26) What is meant by 180 day exclusivity?

The Hatch-Waxman Amendments provide an incentive of 180 days of market exclusivity to the “first” generic applicant who challenges a listed patent by filing a paragraph IV certification and thereby runs the risk of having to defend a patent infringement suit.

180 Day Exclusivity could be granted to more than one applicant. The recent example is- 180 day exclusivity was granted to Ranbaxy and Watson Laboratories for marketing generic version of  Lipitor ( Atorvastatin calcium).

27) What are the procedures for Approval of Drug in EU?

Centralised Procedure (CP)

Decentralised Procedure (DCP)

Mutual Recognition Procedure (MRP)

National Procedure (NP)

28) What is the Full form of abbreviation, CEP?

Certificate of Suitability to the monographs of the European Pharmacopoeia (or) Certificate of suitability of monographs of the European Pharmacopoeia (or) Certification of suitability of European Pharmacopoeia monographs

It is also informally referred to as Certificate of Suitability (COS)

29) What is a CEP?

It is the certificate which is issued by Certification of Substances Division of European Directorate for the Quality of Medicines (EDQM), when the manufacturer of a substance provides proof that the quality of the substance is suitably controlled by the relevant monographs of the European Pharmacopoeia.

30) What are the recently approved new Drugs by FDA (Under NDA Chemical Type 1)? (As on 14th March, 2012)

S.NO.NDA #NAME OF DRUGNAME OF ACTIVE INGREDIENTCOMPANY
1203188KALYDECOIVACAFTORVERTEX PHARMS
2203388ERIVEDGEVISMODEGIBGENENTECH
3202324INLYTAAXITINIBPFIZER
4202833PICATOINGENOL MEBUTATELEO PHARMA AS
5202514ZIOPTANTAFLUPROSTMERCK SHARP DOHME
6021746SURFAXINLUCINACTANTDISCOVERY LABORATORIES INC

31) Full forms of some of the Abbreviations related to Regulatory Affairs-

S.No.AbbreviationFull Form
1NDANew Drug Application
2ANDAAbbreviated New Drug application
3IND Investigational New Drug Application
4DMFDrug Master file
5ASMFActive Substance Master File
6MAAMarketing Authorisation Application
7CEPCertificate of Suitability to the monographs of the European Pharmacopoeia
8ICHThe International Conference on Harmonisation of technical requirements for registration of Pharmaceuticals for human use.
9CTDCommon technical document for the registration of pharmaceuticals for human use.
10APApplicant’s Part
11RPRestricted Part
12OPOpen Part
13CPClosed Part
14NMENew Molecular Entity
15NCENew Chemical Entity
16SmPCSummary of Product Characteristics
17PLPackaging Leaflet
18RMSReference Member State
19CMSConcerned Member State
20CHMPThe Committee for Medicinal Products for Human Use
21CPMPCommittee for Proprietary Medicinal Products
22CVMPCommittee For Medicinal Products For Veterinary Use
23SUPACScale-up and post approval changes
24BACPACBulk Active Chemicals Post approval Changes
25cGMPCurrent good Manufacturing Practice
26GCPGood clinical Practice
27GLPGood Laboratory Practice

32) Well known Drug Regulatory Agencies across the world-

S.No.Country /Region                               Regulatory Agency
1United States of AmericaUnited States Food and Drug Administration (USFDA)
2United KingdomMedicines and Healthcare products Regulatory Agency (MHRA)
3European UnionEuropean Medicines Agency (EMA)
4European UnionEuropean Directorate for the Quality of Medicines (EDQM)
5AustraliaTherapeutic Goods Administration (TGA)
6CanadaTherapeutic Products Directorate  (TPD) in Health Product and food branch (HPFB) of Health Canada (HC)
7JapanPharmaceutical and Medical Devices Agency (PMDA)
8FranceAgence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS)Translated into English as- French Agency for the Safety of Health Products
9GermanyBundesinstitut für Arzneimittel und Medizinprodukte, (BfArM)Tanslated into English as- Federal Institute for Drugs and Medical Devices
10BrazilAgência Nacional de Vigilância Sanitária (ANVISA)Tanslated into English as- The National Health Surveillance Agency
11IndiaDrugs Controller General of India (DCGI) who heads Central Drugs Standard Control Organisation (CDSCO)
12SwitzerlandSwiss Agency for Therapeutic Products (SWISSMEDIC)
14SingaporeHealth Sciences Authority (HSA)
15New ZealandNew Zealand Medicines and Medical Devices Safety Authority (MEDSAFE)

 

More Pharma Jobs :-

LEAVE A REPLY

Please enter your comment!
Please enter your name here